Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Reich

Showing results (291-300 of 316) with videos related to

Pageof 32
Sort By:
Postepy Dermatologii I Alergologii|May 30, 2020
Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part I. Prophylaxis, topical treatment and phototherapyRoman J Nowicki, Magdalena Trzeciak, Maciej Kaczmarski, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2025
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysisFranz J Legat, Shawn G Kwatra, Adam Reich, et al.
Journal of Clinical Medicine|March 10, 2022
Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of LifeDorota Purzycka-Bohdan, Anna Kisielnicka, Monika Zabłotna, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.
The New England Journal of Medicine|October 27, 2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo NodularisShawn G Kwatra, Gil Yosipovitch, Franz J Legat, et al.
Cancers|July 9, 2022
Risk Factors and Clinicopathological Features for Developing a Subsequent Primary Cutaneous Squamous and Basal Cell CarcinomasMagdalena Ciążyńska, Marta Pabianek, Martyna Sławińska, et al.
Scientific Reports|October 29, 2020
Clinical and epidemiological analysis of basosquamous carcinoma: results of the multicenter studyMagdalena Ciążyńska, Martyna Sławińska, Grażyna Kamińska-Winciorek, et al.
International Journal of Molecular Sciences|July 9, 2022
The Analysis of a Genome-Wide Association Study (GWAS) of Overweight and Obesity in PsoriasisAnna Kisielnicka, Marta Sobalska-Kwapis, Dorota Purzycka-Bohdan, et al.
JAMA Dermatology|November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 TrialSonja Ständer, Gil Yosipovitch, Franz J Legat, et al.
Frontiers in Medicine|July 4, 2024
Disease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD Experts) Delphi panelMagdalena Trzeciak, Lidia Rudnicka, Petr Arenberger, et al.
Pageof 32

Showing results (291-300 of 316) with videos related to

Sort By:
Pageof 32
Postepy Dermatologii I Alergologii|May 30, 2020
Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part I. Prophylaxis, topical treatment and phototherapyRoman J Nowicki, Magdalena Trzeciak, Maciej Kaczmarski, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2025
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysisFranz J Legat, Shawn G Kwatra, Adam Reich, et al.
Journal of Clinical Medicine|March 10, 2022
Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of LifeDorota Purzycka-Bohdan, Anna Kisielnicka, Monika Zabłotna, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.
The New England Journal of Medicine|October 27, 2023
Phase 3 Trial of Nemolizumab in Patients with Prurigo NodularisShawn G Kwatra, Gil Yosipovitch, Franz J Legat, et al.
Cancers|July 9, 2022
Risk Factors and Clinicopathological Features for Developing a Subsequent Primary Cutaneous Squamous and Basal Cell CarcinomasMagdalena Ciążyńska, Marta Pabianek, Martyna Sławińska, et al.
Scientific Reports|October 29, 2020
Clinical and epidemiological analysis of basosquamous carcinoma: results of the multicenter studyMagdalena Ciążyńska, Martyna Sławińska, Grażyna Kamińska-Winciorek, et al.
International Journal of Molecular Sciences|July 9, 2022
The Analysis of a Genome-Wide Association Study (GWAS) of Overweight and Obesity in PsoriasisAnna Kisielnicka, Marta Sobalska-Kwapis, Dorota Purzycka-Bohdan, et al.
JAMA Dermatology|November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 TrialSonja Ständer, Gil Yosipovitch, Franz J Legat, et al.
Frontiers in Medicine|July 4, 2024
Disease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD Experts) Delphi panelMagdalena Trzeciak, Lidia Rudnicka, Petr Arenberger, et al.
Pageof 32